SK154199A3 - A method for the treatment of mental illness in mammals and a composition therefor - Google Patents

A method for the treatment of mental illness in mammals and a composition therefor Download PDF

Info

Publication number
SK154199A3
SK154199A3 SK1541-99A SK154199A SK154199A3 SK 154199 A3 SK154199 A3 SK 154199A3 SK 154199 A SK154199 A SK 154199A SK 154199 A3 SK154199 A3 SK 154199A3
Authority
SK
Slovakia
Prior art keywords
stress
adrenoreceptor
selective
induced
test
Prior art date
Application number
SK1541-99A
Other languages
English (en)
Slovak (sk)
Inventor
Antti Haapalinna
Timo Viitamaa
Jukka Sallinen
Mika Scheinin
Juha-Matti Savola
Original Assignee
Antti Haapalinna
Timo Viitamaa
Jukka Sallinen
Mika Scheinin
Savola Juha Matti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antti Haapalinna, Timo Viitamaa, Jukka Sallinen, Mika Scheinin, Savola Juha Matti filed Critical Antti Haapalinna
Publication of SK154199A3 publication Critical patent/SK154199A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK1541-99A 1997-05-12 1998-05-11 A method for the treatment of mental illness in mammals and a composition therefor SK154199A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/854,730 US5902807A (en) 1997-05-12 1997-05-12 Method for the treatment of mental illness in mammals and a composition therefor
PCT/FI1998/000398 WO1998051310A1 (en) 1997-05-12 1998-05-11 A method for the treatment of mental illness in mammals and a composition therefor

Publications (1)

Publication Number Publication Date
SK154199A3 true SK154199A3 (en) 2001-01-18

Family

ID=25319419

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1541-99A SK154199A3 (en) 1997-05-12 1998-05-11 A method for the treatment of mental illness in mammals and a composition therefor

Country Status (12)

Country Link
US (1) US5902807A (hu)
EP (1) EP1003518A1 (hu)
JP (1) JP2001524979A (hu)
AU (1) AU744096B2 (hu)
BR (1) BR9808784A (hu)
CA (1) CA2288650C (hu)
EE (1) EE03667B1 (hu)
HU (1) HUP0002346A3 (hu)
NO (1) NO995469L (hu)
PL (1) PL336771A1 (hu)
SK (1) SK154199A3 (hu)
WO (1) WO1998051310A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
MXPA04009601A (es) * 2002-04-03 2004-12-13 Orion Corp Compuestos policiclicos como potentes antagonistas del adreno-receptor alfa-2.
ATE521593T1 (de) * 2002-04-03 2011-09-15 Orion Corp Verwendung eines alfa2-adrenorezeptorantagonisten bei mit dem zns zusammenhängenden erkrankungen
PT1542670E (pt) * 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) * 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) * 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
EP3593797A1 (en) * 2006-12-28 2020-01-15 Suntory Holdings Limited Nerve-regenerating agent
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤

Also Published As

Publication number Publication date
AU744096B2 (en) 2002-02-14
HUP0002346A1 (hu) 2001-05-28
AU7433498A (en) 1998-12-08
WO1998051310A1 (en) 1998-11-19
PL336771A1 (en) 2000-07-17
NO995469D0 (no) 1999-11-08
HUP0002346A3 (en) 2001-09-28
NO995469L (no) 1999-11-08
EE9900561A (et) 2000-06-15
EE03667B1 (et) 2002-04-15
EP1003518A1 (en) 2000-05-31
CA2288650A1 (en) 1998-11-19
JP2001524979A (ja) 2001-12-04
US5902807A (en) 1999-05-11
BR9808784A (pt) 2000-08-01
CA2288650C (en) 2007-09-25

Similar Documents

Publication Publication Date Title
Takahashi et al. Antagonism of CRF2 receptors produces anxiolytic behavior in animal models of anxiety
Rivat et al. Chronic stress induces transient spinal neuroinflammation, triggering sensory hypersensitivity and long-lasting anxiety-induced hyperalgesia
Elhabazi et al. Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments
Zarrindast et al. The effects of dopaminergic drugs in the ventral hippocampus of rats in the nicotine-induced anxiogenic-like response
SK154199A3 (en) A method for the treatment of mental illness in mammals and a composition therefor
Hubbard et al. Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear
JP2010531879A (ja) 水素化ピリド［４，３−ｂ］インドールに基づく抗不安作用を示す薬物、その薬理学的な化合物および適用方法
CZ228295A3 (en) The use of carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
JP2018008993A (ja) 認知機能を改善するための方法および組成物
Li et al. Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy
JP6433482B2 (ja) 認知機能を改善するための方法および組成物
US20130045988A1 (en) Combination therapy
Soleimannejad et al. Microinjection of ritanserin into the dorsal hippocampal CA1 and dentate gyrus decrease nociceptive behavior in adult male rat
Sorbera et al. Pagoclone
Bustamante-García et al. Anxiolytic-like effects of a new 1-N substituted analog of melatonin in pinealectomized rats
Nazar et al. Benzodiazepine-GABA A receptor complex ligands in two models of anxiety
Lamtahri et al. The gliopeptide ODN, a ligand for the benzodiazepine site of GABAA receptors, boosts functional recovery after stroke
Ceyhan et al. Investigation of the effects of tianeptine and fluoxetine on pentylenetetrazole-induced seizures in rats
De Sarro et al. Effects of antiepileptic drugs, calcium channel blockers and other compounds on seizures induced by activation of voltage-dependent L calcium channel in DBA/2 mice
Cook et al. Selective GABAAα5 benzodiazepine inverse agonist antagonizes the neurobehavioral actions of alcohol
Groenink et al. CRF1 not glucocorticoid receptors mediate prepulse inhibition deficits in mice overexpressing CRF
Brocco et al. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents
Lazartigues et al. Pressor and bradycardic effects of tacrine and other acetylcholinesterase inhibitors in the rat
KR20160030506A (ko) 만성 외상성 뇌질환-i을 예방 및/또는 치료하는 방법
Corda et al. Proconflict effect of ACTH1− 24: Interaction with benzodiazepines